secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001493152-26-014834
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine's LPCN 1154 Phase 3 PPD trial misses primary endpoint; post hoc signals
--------------------------------------------------------------------------------

- Primary endpoint not met: no statistically significant HAM-D17 reduction vs placebo at hour 60 in full population (N=90).
- Post hoc analysis of participants with psychiatric history (n=54) showed nominal significant reductions from hour 12 through day 30.
- LPCN 1154 was well tolerated; no SAEs, excessive sedation, or treatment-related discontinuations reported.
- Company evaluating all options, including further LPCN 1154 development, strategic transactions, and FDA designations (breakthrough/fast track applied).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226014834/0001493152-26-014834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226014834/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer